159 related articles for article (PubMed ID: 35608481)
1. Trials, Tribunals, and Opportunities for Lung Cancer KRASG12C Brain Metastases.
Kommalapati A; Mansfield AS
Clin Cancer Res; 2022 Aug; 28(15):3179-3181. PubMed ID: 35608481
[TBL] [Abstract][Full Text] [Related]
2. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.
Sabari JK; Velcheti V; Shimizu K; Strickland MR; Heist RS; Singh M; Nayyar N; Giobbie-Hurder A; Digumarthy SR; Gainor JF; Rajan AP; Nieblas-Bedolla E; Burns AC; Hallin J; Olson P; Christensen JG; Kurz SC; Brastianos PK; Wakimoto H
Clin Cancer Res; 2022 Aug; 28(15):3318-3328. PubMed ID: 35404402
[TBL] [Abstract][Full Text] [Related]
3. Adagrasib Response Remains Strong in NSCLC.
Cancer Discov; 2022 Aug; 12(8):OF1. PubMed ID: 35666594
[TBL] [Abstract][Full Text] [Related]
4. Safety and Intracranial Activity of Adagrasib in Patients With
Bernstein E; Luo J; Wang K; Negrao MV; Jänne PA; Sabari JK
JCO Precis Oncol; 2024 Feb; 8():e2300447. PubMed ID: 38330263
[No Abstract] [Full Text] [Related]
5. Practical Guidance for the Management of Adverse Events in Patients with KRASG12C-Mutated Non-Small Cell Lung Cancer Receiving Adagrasib.
Zhang J; Johnson M; Barve M; Bazhenova L; McCarthy M; Schwartz R; Horvath-Walsh E; Velastegui K; Qian C; Spira A
Oncologist; 2023 Apr; 28(4):287-296. PubMed ID: 36892150
[TBL] [Abstract][Full Text] [Related]
6. Adagrasib's Efficacy Sustained in KRASG12C NSCLC.
Cancer Discov; 2023 Nov; 13(11):OF1. PubMed ID: 37702568
[TBL] [Abstract][Full Text] [Related]
7. A saturation mutagenesis screen uncovers resistant and sensitizing secondary
Feng S; Callow MG; Fortin JP; Khan Z; Bray D; Costa M; Shi Z; Wang W; Evangelista M
Proc Natl Acad Sci U S A; 2022 May; 119(18):e2120512119. PubMed ID: 35471904
[TBL] [Abstract][Full Text] [Related]
8. Clinical Acquired Resistance to KRAS
Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
[TBL] [Abstract][Full Text] [Related]
9.
Ceddia S; Landi L; Cappuzzo F
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012655
[No Abstract] [Full Text] [Related]
10. Adagrasib in Non-Small-Cell Lung Cancer.
Kotecha R; Sahgal A; Mehta MP
N Engl J Med; 2022 Sep; 387(13):1238-1239. PubMed ID: 36170508
[No Abstract] [Full Text] [Related]
11. Adagrasib in Non-Small-Cell Lung Cancer. Reply.
Jänne PA; Sabari JK; Spira AI
N Engl J Med; 2022 Sep; 387(13):1238-1239. PubMed ID: 36170509
[No Abstract] [Full Text] [Related]
12. Limited role of
Li HS; Liu CM; Wang Y
Future Oncol; 2022 Jun; 18(19):2433-2443. PubMed ID: 35440164
[TBL] [Abstract][Full Text] [Related]
13. Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer.
Manabe T; Bivona TG
J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166243
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of the GTPase KRAS
Xu Q; Zhang G; Liu Q; Li S; Zhang Y
Expert Opin Ther Pat; 2022 May; 32(5):475-505. PubMed ID: 35062845
[TBL] [Abstract][Full Text] [Related]
17. Targeting Mutated KRAS Genes to Treat Solid Tumours.
Krishnan T; Roberts-Thomson R; Broadbridge V; Price T
Mol Diagn Ther; 2022 Jan; 26(1):39-49. PubMed ID: 34914038
[TBL] [Abstract][Full Text] [Related]
18. The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib.
Patil T; Smith DE; Bunn PA; Aisner DL; Le AT; Hancock M; Purcell WT; Bowles DW; Camidge DR; Doebele RC
J Thorac Oncol; 2018 Nov; 13(11):1717-1726. PubMed ID: 29981925
[TBL] [Abstract][Full Text] [Related]
19. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
[TBL] [Abstract][Full Text] [Related]
20. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases.
Mak KS; Gainor JF; Niemierko A; Oh KS; Willers H; Choi NC; Loeffler JS; Sequist LV; Shaw AT; Shih HA
Neuro Oncol; 2015 Feb; 17(2):296-302. PubMed ID: 25053852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
